Stock listing

NASDAQ:KLRA Kailera Therapeutics, Inc. Stock

Home listing (NASDAQ) of Kailera Therapeutics, Inc.

Follow Kailera Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:KLRA

$11.02 USD -0.77 (-6.5%)

Close on Nov 20, 2026

Past 6 months -31.1% · daily closes, Apr 16, 2026 – Nov 20, 2026, adjusted for splits
Day range
$11.00 – $11.87 USDNov 20, 2026
Volume
553,229 sharesNov 20, 2026
Market cap
$1.43B USDAt the close on Nov 20, 2026 · price × 129.9M shares outstanding
Traded on an average day
$13.73M USDMedian day 962,425 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Kailera Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KLRA · Home$11.02 USD-0.77 (-6.5%)553,229$11.29$11.87$11.00$11.79Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KLRA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$11.02-0.77-6.5%$11.29$11.87$11.00553,229
$11.79-0.41-3.4%$12.28$12.51$11.79418,798
$12.20-0.37-2.9%$12.46$12.68$11.86510,056
$12.57-0.70-5.3%$12.91$13.31$12.47962,425
$13.27+0.06+0.5%$13.21$13.62$12.78536,741
$13.21-1.17-8.1%$14.31$14.31$13.19563,116
$14.38+0.14+1.0%$14.30$14.62$14.00609,999
$14.24+0.54+3.9%$13.72$14.89$13.391,182,697
$13.70+0.73+5.6%$13.42$14.33$13.011,366,417
$12.97+0.80+6.6%$12.29$13.26$11.97733,038
$12.17-0.63-4.9%$13.30$13.30$11.93842,152
$12.80+0.22+1.7%$13.02$13.19$12.15651,264
$12.58+0.43+3.5%$12.32$12.99$12.30775,937
$12.15-0.71-5.5%$12.94$13.02$11.96881,410
$12.86-0.55-4.1%$13.27$13.40$12.54868,347
$13.41-0.01-0.1%$13.49$13.83$13.301,037,482
$13.42+0.29+2.2%$13.04$13.44$12.73876,003
$13.13+0.36+2.8%$12.94$13.27$12.56841,655
$12.77-0.08-0.6%$12.85$13.14$12.62588,890
$12.85-0.42-3.2%$13.18$13.18$12.461,560,600
$13.27+0.35+2.7%$12.80$13.34$12.56855,500
$12.92+0.03+0.2%$12.91$13.22$12.701,282,800
$12.89+1.46+12.8%$11.43$13.06$11.431,580,000
$11.43+0.18+1.6%$11.34$11.69$11.18896,600
$11.25-0.46-3.9%$11.75$11.79$11.161,299,400
$11.71+0.97+9.0%$10.61$11.76$10.501,174,300
$10.74-0.03-0.3%$10.64$10.99$10.441,304,800
$10.77-0.56-4.9%$11.31$11.44$10.721,106,600
$11.33-0.28-2.4%$11.39$11.70$10.981,220,400
$11.61+1.61+16.1%$10.13$11.81$9.982,181,200
$10.00-0.53-5.0%$10.42$10.42$9.761,532,200
$10.53-0.30-2.8%$10.77$11.12$10.501,091,700
$10.83-0.01-0.1%$10.95$11.24$10.321,452,000
$10.84+0.45+4.3%$10.48$11.04$9.851,811,900
$10.39-0.64-5.8%$11.23$11.40$10.291,280,900
$11.03-0.39-3.4%$11.39$11.76$10.572,187,200
$11.42+0.43+3.9%$11.16$11.67$10.861,368,800
$10.99-0.13-1.2%$11.10$11.31$10.83694,100
$11.12-0.10-0.9%$11.30$11.52$11.071,433,500
$11.22-0.76-6.3%$11.80$12.33$11.101,722,600
$11.98-1.15-8.8%$12.85$13.12$11.772,761,200
$13.13+0.34+2.7%$12.76$13.22$12.561,631,800
$12.79+0.80+6.7%$12.46$12.95$12.051,230,000
$11.99-0.84-6.5%$12.95$13.04$11.841,050,200
$12.83-0.09-0.7%$12.98$13.23$12.363,164,400
$12.92+0.22+1.7%$13.07$13.21$12.631,036,200
$12.70-0.75-5.6%$13.55$13.68$12.471,134,500
$13.45-0.30-2.2%$13.71$13.98$13.32726,400
$13.75-0.19-1.4%$13.91$14.12$13.56872,400
$13.94-0.97-6.5%$15.10$15.40$13.90815,400
$14.91+0.07+0.5%$14.58$14.98$14.51661,400
$14.84-1.59-9.7%$16.27$16.32$14.76743,700
$16.43+0.20+1.2%$15.79$16.63$15.621,000,500
$16.23+0.49+3.1%$15.60$16.44$15.57523,300
$15.74-0.11-0.7%$15.95$16.51$15.50642,500
$15.85-0.56-3.4%$16.39$16.82$15.59737,300
$16.41+1.01+6.6%$15.21$17.06$15.151,200,800
$15.40-0.81-5.0%$16.26$16.64$15.151,144,000
$16.21-2.32-12.5%$18.26$18.26$16.19532,000
$18.53+0.09+0.5%$18.31$18.78$17.76439,600
$18.44+0.69+3.9%$17.71$18.47$17.37785,300
$17.75+1.21+7.3%$16.75$18.19$16.541,323,874
$16.54-0.63-3.7%$17.14$17.16$16.37549,546
$17.17-0.29-1.7%$17.52$17.96$17.00436,800
$17.46-0.86-4.7%$18.20$18.37$17.17544,900
Ticker
NASDAQ:KLRA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Kailera Therapeutics, Inc. news

Kailera Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 15 in all · newest Nov 10, 2026 · oldest 2026
Decks
5 decks · latest September 2026

Where Kailera Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KLRA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:KLRABOATSUnited StatesUSD

Valuation

Price/book 1.4× against a median of 2.5×: 2nd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$539.5M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.28

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Kailera Therapeutics, Inc. · NASDAQ:KLRAUS$1.43BUS$539.5Mn/an/an/a1.4×n/a0.0×1.28
PELL Bio-Med Technology Co Ltd · TWSE:6949US$1.46BUS$1.40Bn/a1,591×n/a18.7×n/a0.1×n/a
Mesoblast Limited · ASX:MSBUS$1.46BUS$1.42Bn/a82.4×n/a2.4×−593.9%0.2×n/a
Voronoi, Inc. · KRX:310210US$1.44BUS$1.40Bn/an/an/a27.9×n/a0.5×n/a
Damora Therapeutics, Inc. · NASDAQ:DMRAUS$1.44BUS$910.0Mn/an/an/a2.9×n/a0.0×0.88
Vir Biotechnology, Inc. · NASDAQ:VIRUS$1.44BUS$1.07Bn/a3.5×n/a1.6×−61.0%0.1×1.82
LigaChem Biosciences Inc. · KRX:141080US$1.43BUS$1.15Bn/a15.5×n/a4.8×−180.9%0.0×n/a
Sarepta Therapeutics, Inc. · NASDAQ:SRPTUS$1.43BUS$1.41Bn/a0.7×n/a0.9×−5.9%0.6×1.70
ADARx Pharmaceuticals, Inc. · NASDAQ:ADRXUS$1.42BUS$521.8Mn/a77.6×n/a2.5×n/a0.0×n/a
Nurix Therapeutics, Inc. · NASDAQ:NRIXUS$1.40BUS$683.6M4.8×1.0×n/a1.4×42.0%0.0×1.15
Intellia Therapeutics, Inc. · NASDAQ:NTLAUS$1.40BUS$1.00Bn/a19.0×n/a2.3×−805.7%0.1×2.01
Median of the othersUS$1.43BUS$1.11B4.8×17.2×2.5×−121.0%0.1×1.70

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
43.00 USD · Analysts' mean
EPS, year to Dec 2026
-4.13 · 5 analysts

Team and board

Officers

OfficerRole
Ron RenaudPresident & Chief Executive Officer
Doug PagánChief Financial Officer
Paul BurgessChief Operating Officer & Chief Business Officer
Scott AkamineChief Legal Officer
Maura GavaghanVice President, Investor Relations
Anna RobinsonVice President, Communications
Jamie ColemanChief Commercial Officer
Kathleen TregoningChief Corporate Affairs Officer
Martin MackayCo-Founder and Chair of Board, Rallybio Corporation
Nur NicholsonChief Technology Officer
Paula CloghessyChief People Officer
Scott WassermanChief Medical Officer

Board

DirectorRole
John F. MilliganBoard Chair
Martin MackayCo-Founder and Chair of Board, Rallybio Corporation
Adam KoppelPartner, Bain Capital Life Sciences
Andrew KaplanPartner, Bain Capital Private Equity
Christopher HiteIndependent Board Member
Frank K. ClyburnDirector

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−4.9%
Q2 2026Aug 12, 2026 · After close−3.3%
Q1 2026May 26, 2026 · After close+1.6%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2026)Technical19 slidesSeptember 2026
Technical Presentation (September 2026)Technical6 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck38 slidesAugust 2026
Investor Presentation (May 2026)Investor deck40 slidesMay 2026
Technical Presentation (September 2024)Technical12 slidesSeptember 2024

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$718.8M raised · US$16 a share · J.P. Morgan +5
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), William Blair
Apr 20, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Apr 16, 2026.

Price
US$16.00 a share
Shares offered
39,062,500 shares of common stock
Offering size
US$625 million
Underwriters' option
Up to 5,859,375 more shares
Listing
KLRA on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI, William Blair · In the order on the cover
Shares delivered
On or about Apr 20, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceDec 19, 2025
Filed publiclyMar 27, 2026
Amended onceApr 13, 2026
Shares registered with an exchangeApr 14, 2026
Declared effective by the SECApr 16, 2026
Final prospectus, with the priceApr 17, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Apr 17, 2026

Financials

Annual, in USD

Income statement

LineFY2025
Revenue0
Research and development109.1M
Selling, general and administrative49.2M
Operating income-158.3M
Depreciation and amortization310.0K
EBITDA-158.0M
Income before tax-149.0M
Net income-149.0M
Earnings per share, basic-1.26

Balance sheet

LineFY2025FY2024
Cash and equivalents160.3M175.2M
Short-term investments385.8M0
Receivables2.73M
Current assets557.5M177.6M
Total assets692.3M178.4M
Accounts payable7.53M2.01M
Current liabilities46.4M6.91M
Total debt10.8M
Total liabilities1.05B397.2M
Shareholders' equity-356.5M-218.8M
Shares outstanding117.9M117.9M

Cash flow

LineFY2025
Cash from operations-120.2M
Capital spending-2.09M
Free cash flow-122.3M
Cash from investing-492.6M
Cash from financing598.7M
Change in cash-14.2M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 9, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 5, 2026Big-stake noticeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
All 64 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
10-Q · Quarterly reportMay 26, 2026Quarterly reportSEC
8-K · Current reportMay 26, 2026ResultsSEC
SCHEDULE 13D · Big-stake noticeApr 23, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeApr 23, 2026Big-stake noticeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
8-K · Current reportApr 20, 2026Current reportSEC
424B4 · ProspectusApr 17, 2026Offer documentSEC
S-8 · Registration statement for employee plansApr 17, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 17, 2026Other filingsSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringApr 16, 2026Offer documentSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
CERT · Exchange's certificate of listingApr 15, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeApr 14, 2026Other filingsSEC
S-1/A · Registration statement, amendedApr 13, 2026Offer documentSEC
S-1 · Registration statementMar 27, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedFeb 11, 2026Offer documentSEC
DRS · Draft registration statementDec 19, 2025Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Kailera Therapeutics, Inc.’s releases · as of Oct 29, 2026

Common shares
129,850,481
Fully diluted
129,850,481

Fully diluted

LineSharesAs of
Common shares129,850,481Oct 29, 2026

Share count over time

CountShares
Oct 29, 2026129,850,481

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Bain Capital Investors LLC26.3M20.2%US$300MSep 30, 2026
Bain Capital Life Sciences Investors, LLC22.6M17.4%US$258MSep 30, 2026
Rtw Investments, LP10.8M8.3%US$123MSep 30, 2026
CPP Investments7.3M5.6%US$83.4MSep 30, 2026
Atlas Venture Life Science Advisors, LLC5.17M4.0%US$59.1MSep 30, 2026
Fidelity4.66M3.6%US$53.2MSep 30, 2026
BlackRock4.57M3.5%US$52.2MSep 30, 2026
Adage Capital Partners Gp, L.L.C.4.17M3.2%US$47.7MSep 30, 2026
Citadel3.65M2.8%US$41.7MSep 30, 2026
Vanguard3.64M2.8%US$41.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Royalty Pharma Sub-Manager, LLC2.46M1.9%US$28MSep 30, 2026
State Street2.24M1.7%US$25.6MSep 30, 2026
Siren, L.L.C.2.21M1.7%US$25.3MSep 30, 2026
Ameriprise2.09M1.6%US$23.9MSep 30, 2026
Geode Capital1.21M0.93%US$13.8MSep 30, 2026
Frazier Life Sciences Management, L.P.1.2M0.92%US$13.7MSep 30, 2026
Farallon Capital Management, L.L.C.1.1M0.85%US$12.6MSep 30, 2026
Trails Edge Capital Partners, LP943K0.73%US$10.8MSep 30, 2026
Marshall Wace, LLP878K0.68%US$10MSep 30, 2026
Millennium859K0.66%US$9.81MSep 30, 2026
Goldman Sachs697K0.54%US$7.95MSep 30, 2026
T. Rowe Price632K0.49%US$7.22MSep 30, 2026
Vestal Point Capital, LP625K0.48%US$7.14MSep 30, 2026
UBS498K0.38%US$5.68MSep 30, 2026
Catalio Capital Management, LP469K0.36%US$5.35MSep 30, 2026
abrdn433K0.33%US$4.94MSep 30, 2026
Walleye Capital LLC417K0.32%US$4.76MSep 30, 2026
Bank of America408K0.31%US$4.66MSep 30, 2026
Federated Hermes, Inc.404K0.31%US$4.61MSep 30, 2026
Franklin Templeton401K0.31%US$5.14MSep 30, 2026
Cormorant Asset Management, LP400K0.31%US$4.57MSep 30, 2026
Schwab385K0.30%US$4.39MSep 30, 2026
Jump Financial, LLC381K0.29%US$4.35MSep 30, 2026
Northern Trust361K0.28%US$4.13MSep 30, 2026
Janus Henderson346K0.27%US$3.95MSep 30, 2026
BNP Paribas310K0.24%US$3.54MSep 30, 2026
Wellington272K0.21%US$3.11MSep 30, 2026
Exchange Traded Concepts, LLC261K0.20%US$2.98MSep 30, 2026
Point72 Asset Management, L.P.230K0.18%US$2.63MSep 30, 2026
XTX Topco Ltd228K0.18%US$2.61MSep 30, 2026
Renaissance Technologies199K0.15%US$2.27MSep 30, 2026
Seven Grand Managers, LLC175K0.13%US$2MSep 30, 2026
Alps Advisors Inc172K0.13%US$1.96MSep 30, 2026
Morgan Stanley155K0.12%US$1.77MSep 30, 2026
Hrt Financial LP151K0.12%US$1.72MSep 30, 2026
Nuveen147K0.11%US$1.68MSep 30, 2026
BNY141K0.11%US$1.61MSep 30, 2026
a16z Capital Management, L.L.C.140K0.11%US$1.6MSep 30, 2026
Nantahala Capital Management, LLC140K0.11%US$1.6MSep 30, 2026
Citigroup Inc112K0.09%US$1.28MSep 30, 2026

This page holds 50 of 126 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Health Care Fund2.19M1.7%US$37.1MJul 31, 2026
Vanguard Total Stock Market Index Fund1.18M0.91%US$26MJun 30, 2026
iShares Russell 2000 ETF1.16M0.90%US$25.6MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.904K0.70%US$19.9MJun 30, 2026
Vanguard Small-Cap Index Fund850K0.65%US$18.7MJun 30, 2026
Fidelity Growth Company Fund753K0.58%US$17.3MMay 31, 2026
Columbia Small Cap Growth Fund652K0.50%US$15MMay 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund635K0.49%US$14MJun 30, 2026
Select Biotechnology Portfolio619K0.48%US$14.2MMay 31, 2026
Eventide Healthcare & Life Sciences Fund617K0.47%US$13.6MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Blue Chip Growth Fund587K0.45%US$9.95MJul 31, 2026
Fidelity Small Cap Index Fund504K0.39%US$8.54MJul 31, 2026
Vanguard Small-Cap Growth Index Fund488K0.38%US$10.8MJun 30, 2026
Vanguard Extended Market Index Fund476K0.37%US$10.5MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio464K0.36%US$10.6MMay 29, 2026
Federated Hermes Kaufmann Small Cap Fund404K0.31%US$6.84MJul 31, 2026
T. Rowe Price New Horizons Fund, Inc.368K0.28%US$8.1MJun 30, 2026
iShares Russell 2000 Growth ETF291K0.22%US$6.42MJun 30, 2026
Fidelity Balanced Fund262K0.20%US$6.01MMay 31, 2026
Fidelity Growth Company K6 Fund209K0.16%US$4.8MMay 31, 2026
Fidelity Series Growth Company Fund197K0.15%US$4.51MMay 31, 2026
Vanguard Explorer Fund161K0.12%US$2.72MJul 31, 2026
Roundhill GLP-1 & Weight Loss ETF153K0.12%US$3.36MJun 30, 2026
Franklin Biotechnology Discovery Fund146K0.11%US$2.48MJul 31, 2026
iShares Russell 2000 Value ETF137K0.11%US$3.01MJun 30, 2026
The Hartford Healthcare Fund133K0.10%US$2.26MJul 31, 2026
Fidelity Blue Chip Growth K6 Fund120K0.09%US$2.04MJul 31, 2026
Schwab Small-Cap Index Fund111K0.09%US$1.89MJul 31, 2026
Fidelity Series Blue Chip Growth Fund109K0.08%US$1.85MJul 31, 2026
Master Small Cap Index Series86,3130.07%US$1.9MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund82,7000.06%US$1.9MMay 31, 2026
T.Rowe Price Small Cap Growth Portfolio71,4020.05%US$1.57MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF61,7300.05%US$1.36MJun 30, 2026
Nuveen Small Cap Blend Index Fund61,1430.05%US$1.04MJul 31, 2026
T. Rowe Price Health Sciences Portfolio55,6640.04%US$1.23MJun 30, 2026
Health Sciences Portfolio55,1170.04%US$1.21MJun 30, 2026
EQ/2000 Managed Volatility Portfolio49,7240.04%US$1.1MJun 30, 2026
Transamerica T. Rowe Price Small Cap VP45,9630.04%US$1.01MJun 30, 2026
Columbia Variable Portfolio - Small Company Growth Fund44,5210.03%US$981KJun 30, 2026
Fidelity Blue Chip Growth ETF44,0170.03%US$746KJul 31, 2026
Health Sciences Trust33,0690.03%US$729KJun 30, 2026
LVIP State Street Small-Cap Index Fund32,9000.03%US$725KJun 30, 2026
Vanguard Russell 2000 Index Fund31,6170.02%US$725KMay 31, 2026
Schwab Total Stock Market Index Fund30,0000.02%US$508KJul 31, 2026
Fidelity Small Cap Growth Index Fund29,7920.02%US$656KJun 30, 2026
Small Company Growth Portfolio28,7520.02%US$633KJun 30, 2026
EQ/Small Company Index Portfolio27,3700.02%US$603KJun 30, 2026
Nuveen Equity Index Fund24,2040.02%US$410KJul 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio23,3070.02%US$513KJun 30, 2026
Small Cap Index Fund23,2830.02%US$513KJun 30, 2026

This page holds 50 of 117 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Rtw Investments, LP
10% owner
Buy500,000USD 16.00US$8MApr 20, 2026
Kaplan Andrew T.
Director, 10% owner
Buy8,398,438USD 16.00US$134MApr 20, 2026
BCLS Fund IV Investments GP, LLC
10% owner
Buy1,562,500USD 16.00US$25MApr 20, 2026
Koppel Adam
Director, 10% owner
Buy1,562,500USD 16.00US$25MApr 20, 2026
BCPE Perseus Investor, LP
10% owner
Buy8,398,438USD 16.00US$134MApr 20, 2026

Big stakes

StakeStakeSharesDateFiling
BCPE Perseus Investor, LP20.27%26.3MApr 16, 2026Schedule 13D
BCLS Fund IV Investments, L.P.17.43%22.6MApr 16, 2026Schedule 13D
Jiangsu Hengrui Pharmaceuticals Co., Ltd.8.90%11.5MJun 30, 2026Schedule 13G
Rtw Investments, LP8.30%10.8MJun 30, 2026Schedule 13G
Canada Pension Plan Investment Board5.60%7.3MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Martin Mackay
Other companies: SpringWorks Therapeutics Inc (Director · Since at least Jul 29, 2024); Rallybio Corporation (Co-Founder and Chairman · Since at least Jul 28, 2021); Charles River Laboratories International, Inc. (Director · Since at least Jul 1, 2017); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & Global Head of R&D · May 13, 2013 – Feb 27, 2017 · Past); Pfizer, Inc. (Senior Vice President · Sep 30, 2008 – May 14, 2010 · Past)
Co-Founder and Chair of Board, Rallybio Corporation · Since at least Apr 16, 2026
Doug Pagán
Other companies: Dicerna Pharmaceuticals Inc (Chief Financial Officer · May 26, 2020 – Dec 28, 2021 · Past); Alaunos Therapeutics, Inc. (Director · Sep 18, 2018 – Dec 31, 2019 · Past); Paratek Pharmaceuticals Inc (Chief Financial Officer · Dec 18, 2014 – Apr 5, 2019 · Past)
Chief Financial Officer · Since at least Apr 16, 2026
John F. Milligan
Other companies: 4D Molecular Therapeutics, Inc. (Executive Chairman · Since at least Dec 10, 2020); Pacific Biosciences of California, Inc. (Chairman of the Board · Since at least Jul 17, 2013); Gilead Sciences, Inc. (President and CEO, Director · Nov 7, 2013 – Nov 27, 2018 · Past)
Board Chair · Since at least Apr 16, 2026
Kathleen Tregoning
Other companies: COMPASS Pathways Plc (Director · Since at least May 27, 2026); Spero Therapeutics, Inc. (Director · Since at least Jun 12, 2025)
Chief Corporate Affairs Officer · Since at least Jun 29, 2026
Paul Burgess
Other companies: Cerevel Therapeutics Holdings Inc (See Remarks · Jun 20, 2023 – Aug 1, 2024 · Past); Translate Bio Inc (General Counsel and Secretary · Jun 27, 2018 – Jun 27, 2018 · Past)
Chief Operating Officer & Chief Business Officer · Since at least Apr 16, 2026
Nur Nicholson
Other companies: Apellis Pharmaceuticals, Inc. (Chief Technical Officer · Since at least Sep 25, 2020)
Chief Technology Officer · Since at least Aug 11, 2026
Adam KoppelDirector · Since at least Apr 20, 2026
Andrew KaplanDirector · Since at least Apr 20, 2026
Anna RobinsonVice President, Communications · Since at least Nov 3, 2026
Christopher HiteIndependent Board Member · Since at least Nov 5, 2026
All 19 people
PersonSeat
Frank K. ClyburnDirector · Since at least Nov 5, 2026
Jamie ColemanChief Commercial Officer · Since at least Apr 16, 2026
Maura GavaghanVice President, Investor Relations · Since at least Nov 3, 2026
Paula CloghessyChief People Officer · Since at least Apr 16, 2026
Ronald C Renaud JrCEO & President, Director · Since at least Jun 9, 2026
Ron RenaudPresident & Chief Executive Officer · Since at least Jun 11, 2026
Scott AkamineChief Legal Officer · Since at least Apr 16, 2026
Scott WassermanChief Medical Officer · Since at least Sep 30, 2026
Yuting LiuDirector · Since at least Apr 16, 2026

Open People

Log in to ask 6ix AI your own questions about Kailera Therapeutics, Inc.